Home › Compare › PEAR vs EQR

PEAR vs EQR: Dividend Comparison 2026

PEAR yields 6849.32% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEAR wins by $1339387406433213.75M in total portfolio value
10 years
PEAR
PEAR
● Live price
6849.32%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1339387406433213.75M
Annual income
$1,301,993,616,197,644,700,000.00
Full PEAR calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — PEAR vs EQR

📍 PEAR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPEAREQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PEAR + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PEAR pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PEAR
Annual income on $10K today (after 15% tax)
$582,191.78/yr
After 10yr DRIP, annual income (after tax)
$1,106,694,573,767,997,900,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, PEAR beats the other by $1,106,694,573,767,997,900,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PEAR + EQR for your $10,000?

PEAR: 50%EQR: 50%
100% EQR50/50100% PEAR
Portfolio after 10yr
$669693703216606.88M
Annual income
$650,996,808,098,822,400,000.00/yr
Blended yield
97.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PEAR
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$6.50
+22160.3% upside vs current
Range: $5.00 — $8.00
Altman Z
-8.5
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PEAR buys
0
EQR buys
0
No recent congressional trades found for PEAR or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPEAREQR
Forward yield6849.32% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$1339387406433213.75M ✓$47.8K
Annual income after 10y$1,301,993,616,197,644,700,000.00 ✓$5,475.61
Total dividends collected$1336879923883212.75M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$6.50$70.35 ✓

Year-by-year: PEAR vs EQR ($10,000, DRIP)

YearPEAR PortfolioPEAR Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$695,632$684,931.51$11,380$679.82+$684.3K → PEAR
2$45,273,292$44,528,966.00$13,014$837.25+$45.26M → PEAR
3$2,756,897,651$2,708,455,228.62$14,961$1,036.20+$2756.88M → PEAR
4$157,090,270,836$154,140,390,350.12$17,297$1,289.22+$157090.25M → PEAR
5$8,376,539,704,888$8,208,453,115,093.00$20,121$1,613.15+$8376539.68M → PEAR
6$418,028,448,270,623$409,065,550,786,392.40$23,561$2,030.84+$418028448.25M → PEAR
7$19,526,057,962,883,308$19,078,767,523,233,740.00$27,783$2,573.54+$19526057962.86M → PEAR
8$853,759,153,007,212,900$832,866,270,986,927,700.00$33,013$3,284.39+$853759153007.18M → PEAR
9$34,947,467,509,877,550,000$34,033,945,216,159,830,000.00$39,547$4,223.51+$34947467509877.51M → PEAR
10$1,339,387,406,433,213,700,000$1,301,993,616,197,644,700,000.00$47,791$5,475.61+$1339387406433213.75M → PEAR

PEAR vs EQR: Complete Analysis 2026

PEAR — Stock

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

Full PEAR Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PEAR vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PEAR vs SCHDPEAR vs JEPIPEAR vs OPEAR vs KOPEAR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.